TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine GSK580299 in Healthy Female Subjects Aged 10-25 Years.
Brief Summary: Cervical cancer is the second most common cancer among women worldwide. Approximately 500 000 new cases are reported each year worldwide, from which 83% occur in developing countries. The incidence of cervical cancer varies depending on the region of the world. Africa has some of the highest age-standardized incidence and mortality rates in the world (Eastern Africa 42.7 and 34.6 per 100 000; Southern Africa 38.2 and 22.6 per 100 000; Western Africa 29.3 and 23.8 per 100 000; Middle Africa 28.0 and 23.0 per 100 000).

As in the majority of developing countries, organization of cervical cancer screening programs in Africa is difficult to manage, especially in rural areas. HPV prophylactic vaccination could therefore clearly and efficiently decrease the incidence of cervical cancer. The current study is designed to assess the immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 AS04 vaccine in female subjects enrolled from multiple countries in Africa.

Ideally, HPV vaccination should be performed before onset of sexual activity, since studies have shown that acquisition of high-risk HPV occurs soon after sexual debut. This study will therefore be performed in subjects aged 10 to 25 years of age.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18 vaccine (Cervarix™) | Arm Label: Aimmugen Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Aimmugen™ | Intervention Type: BIOLOGICAL; Name: HPV-16/18 vaccine (Cervarix™); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Aimmugen™; Assigned to Arm(s): Aimmugen Group
B: Arm Label: Cervarix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Al(OH)3 | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix Group | Intervention Type: DRUG; Name: Placebo Al(OH)3; Assigned to Arm(s): Placebo Group
C: Arm Label: Cervarix; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18 VLP/AS04 Vaccine (Cervarix TM) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: HPV-16/18 VLP/AS04 Vaccine (Cervarix TM); Assigned to Arm(s): Cervarix
D: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18 L1 VLP AS04 (Cervarix TM) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18 L1 VLP AS04 (Cervarix TM); Assigned to Arm(s): Cervarix Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled Dose-Range Finding Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Brief Summary: A dose-ranging study of MK0431 in patients with type 2 diabetes who have inadequate control of their blood sugar.


Options:
A: Intervention Type: DRUG; Name: MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks; Assigned to Arm(s): N/A
B: Arm Label: Saxagliptin, 5 mg + insulin; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, 5 mg + insulin | Arm Label: Placebo + insulin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + insulin | Intervention Type: DRUG; Name: Saxagliptin, 5 mg + insulin; Assigned to Arm(s): Saxagliptin, 5 mg + insulin | Intervention Type: DRUG; Name: Placebo + insulin; Assigned to Arm(s): Placebo + insulin
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, Drug: Metformin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Metformin | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy of PR OROS Methylphenidate Followed by Open-Label Extension, in Swedish Male Prison Inmates With ADHD
Brief Summary: The purpose of this study is to evaluate the efficacy and effectiveness of methylphenidate in treatment of ADHD in Swedish adult male prison inmates diagnosed with ADHD.


Options:
A: Arm Label: FEM-CARE; Type: EXPERIMENTAL; Interventions: Behavioral: FEM-CARE | Arm Label: Health Promotion; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Promotion | Intervention Type: BEHAVIORAL; Name: FEM-CARE; Assigned to Arm(s): FEM-CARE | Intervention Type: BEHAVIORAL; Name: Health Promotion; Assigned to Arm(s): Health Promotion
B: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: PR OROS Methylphenidate | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PR OROS Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar pill
C: Arm Label: Recovery management intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Recovery management | Intervention Type: BEHAVIORAL; Name: Recovery management; Assigned to Arm(s): Recovery management intervention
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): A, B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy of PR OROS Methylphenidate Followed by Open-Label Extension, in Swedish Male Prison Inmates With ADHD
Brief Summary: The purpose of this study is to evaluate the efficacy and effectiveness of methylphenidate in treatment of ADHD in Swedish adult male prison inmates diagnosed with ADHD.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vigabatrin, Behavioral: Group therapy | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Group therapy | Intervention Type: DRUG; Name: Vigabatrin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B | Intervention Type: BEHAVIORAL; Name: Group therapy; Assigned to Arm(s): A, B
B: Arm Label: Extended-Release Naltrexone (XR-NTX); Type: EXPERIMENTAL; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Enhanced Treatment As Usual (ETAU); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Methadone Treatment Program (MTP); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-Release Naltrexone (XR-NTX)
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Core; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Core | Arm Label: Enhanced; Type: EXPERIMENTAL; Interventions: Behavioral: Core, Behavioral: Enhanced | Intervention Type: BEHAVIORAL; Name: Core; Assigned to Arm(s): Core, Enhanced | Intervention Type: BEHAVIORAL; Name: Enhanced; Assigned to Arm(s): Enhanced
D: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: PR OROS Methylphenidate | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PR OROS Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar pill

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy of PR OROS Methylphenidate Followed by Open-Label Extension, in Swedish Male Prison Inmates With ADHD
Brief Summary: The purpose of this study is to evaluate the efficacy and effectiveness of methylphenidate in treatment of ADHD in Swedish adult male prison inmates diagnosed with ADHD.


Options:
A: Intervention Type: DRUG; Name: methylphenidate hydrochloride extended-release tablets; Assigned to Arm(s): N/A
B: N/A
C: Arm Label: Ritalin LA 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA 20 mg | Arm Label: Ritalin LA 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA 20 mg, Drug: Ritalin LA 30 mg | Arm Label: Ritalin LA 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA 20 mg, Drug: Ritalin LA 30 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ritalin LA 20 mg; Assigned to Arm(s): Ritalin LA 40 mg, Ritalin LA 60 mg, Ritalin LA 80 mg | Intervention Type: DRUG; Name: Ritalin LA 30 mg; Assigned to Arm(s): Ritalin LA 60 mg, Ritalin LA 80 mg
D: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: PR OROS Methylphenidate | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PR OROS Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar pill

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Analgesic Effect of Breast Feeding vs Sucrose in Neonatal Screening
Brief Summary: The purpose of this study is to compare the antinociceptive effect of 1 ml of 30% sucrose solution vs breastfeeding on neonatal screening heel lance


Options:
A: Intervention Type: DRUG; Name: Sucrose solution 30%1 ml; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): N/A
C: Arm Label: Breastfeeding; Type: EXPERIMENTAL; Interventions: Other: Breastfeeding | Arm Label: 24% oral sucrose; Type: ACTIVE_COMPARATOR; Interventions: Drug: 24% oral sucrose | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding | Intervention Type: DRUG; Name: 24% oral sucrose; Assigned to Arm(s): 24% oral sucrose
D: Arm Label: 0.1ml 24% sucrose concurrent opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 0.5ml 24% sucrose concurrent opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 1.0ml 24% sucrose concurrent opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 0.1ml 24% sucrose no opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 0.5ml 24% sucrose no opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 1.0ml 24% sucrose no opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): 0.1ml 24% sucrose concurrent opioids, 0.1ml 24% sucrose no opioids, 0.5ml 24% sucrose concurrent opioids, 0.5ml 24% sucrose no opioids, 1.0ml 24% sucrose concurrent opioids, 1.0ml 24% sucrose no opioids

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Analgesic Effect of Breast Feeding vs Sucrose in Neonatal Screening
Brief Summary: The purpose of this study is to compare the antinociceptive effect of 1 ml of 30% sucrose solution vs breastfeeding on neonatal screening heel lance


Options:
A: Arm Label: sucrose; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: supplemental breast milk; Type: ACTIVE_COMPARATOR; Interventions: Other: supplemental breast milk | Arm Label: Breast feeding; Type: ACTIVE_COMPARATOR; Interventions: Other: breast feeding | Intervention Type: OTHER; Name: breast feeding; Assigned to Arm(s): Breast feeding | Intervention Type: OTHER; Name: supplemental breast milk; Assigned to Arm(s): supplemental breast milk | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): sucrose
B: Arm Label: Oral glucose solution + maternal holding; Type: EXPERIMENTAL; Interventions: Other: Oral glucose solution + maternal holding | Arm Label: Breastfeeding; Type: EXPERIMENTAL; Interventions: Other: Breastfeeding | Arm Label: Oral glucose solution; Type: ACTIVE_COMPARATOR; Interventions: Other: Oral glucose solution | Arm Label: Oral expressed breastmilk; Type: ACTIVE_COMPARATOR; Interventions: Other: Oral expressed breastmilk | Intervention Type: OTHER; Name: Oral glucose solution + maternal holding; Assigned to Arm(s): Oral glucose solution + maternal holding | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding | Intervention Type: OTHER; Name: Oral glucose solution; Assigned to Arm(s): Oral glucose solution | Intervention Type: OTHER; Name: Oral expressed breastmilk; Assigned to Arm(s): Oral expressed breastmilk
C: N/A
D: Intervention Type: DRUG; Name: Sucrose solution 30%1 ml; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Analgesic Effect of Breast Feeding vs Sucrose in Neonatal Screening
Brief Summary: The purpose of this study is to compare the antinociceptive effect of 1 ml of 30% sucrose solution vs breastfeeding on neonatal screening heel lance


Options:
A: Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Sucrose; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Sucrose solution 30%1 ml; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding; Assigned to Arm(s): N/A
D: Arm Label: Noanalgesia; Type: SHAM_COMPARATOR; Interventions: Procedure: Water 2mL PO 2 minutes prior to intra-muscular injection | Arm Label: Skin-to-skin; Type: EXPERIMENTAL; Interventions: Procedure: skin-to-skin contact | Arm Label: Glucose; Type: EXPERIMENTAL; Interventions: Procedure: Glucose 25% 2 mL PO 2 minutes prior to injection | Arm Label: Skin&Glucose; Type: EXPERIMENTAL; Interventions: Procedure: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards. | Intervention Type: PROCEDURE; Name: Water 2mL PO 2 minutes prior to intra-muscular injection; Assigned to Arm(s): Noanalgesia | Intervention Type: PROCEDURE; Name: skin-to-skin contact; Assigned to Arm(s): Skin-to-skin | Intervention Type: PROCEDURE; Name: Glucose 25% 2 mL PO 2 minutes prior to injection; Assigned to Arm(s): Glucose | Intervention Type: PROCEDURE; Name: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.; Assigned to Arm(s): Skin&Glucose

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Analgesic Effect of Breast Feeding vs Sucrose in Neonatal Screening
Brief Summary: The purpose of this study is to compare the antinociceptive effect of 1 ml of 30% sucrose solution vs breastfeeding on neonatal screening heel lance


Options:
A: Arm Label: oral sucrose solution; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Steril water | Arm Label: steril water; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Oral sucrose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: Oral sucrose solution; Assigned to Arm(s): steril water | Intervention Type: DIETARY_SUPPLEMENT; Name: Steril water; Assigned to Arm(s): oral sucrose solution
B: Intervention Type: DRUG; Name: Sucrose solution 30%1 ml; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding; Assigned to Arm(s): N/A
C: Arm Label: sucrose; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: supplemental breast milk; Type: ACTIVE_COMPARATOR; Interventions: Other: supplemental breast milk | Arm Label: Breast feeding; Type: ACTIVE_COMPARATOR; Interventions: Other: breast feeding | Intervention Type: OTHER; Name: breast feeding; Assigned to Arm(s): Breast feeding | Intervention Type: OTHER; Name: supplemental breast milk; Assigned to Arm(s): supplemental breast milk | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): sucrose
D: Arm Label: Sucrose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sucrose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double distilled water | Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): Sucrose | Intervention Type: DRUG; Name: Double distilled water; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known whether radiation therapy and temozolomide are more effective than radiation therapy alone in treating glioblastoma multiforme.

PURPOSE: This randomized phase III trial is studying radiation therapy and temozolomide to see how well they work compared with radiation therapy alone in treating patients with newly diagnosed glioblastoma multiforme.


Options:
A: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiation therapy | Arm Label: Radiotherapy plus Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Radiotherapy plus Bevacizumab | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Radiotherapy
C: Arm Label: Cilengitide + Temozolomide + Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cilengitide, Drug: Temozolomide, Radiation: Radiotherapy | Arm Label: Temozolomide + Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cilengitide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy
D: Arm Label: Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide, Genetic: DNA methylation analysis, Procedure: quality-of-life assessment | Arm Label: Radiation; Type: ACTIVE_COMPARATOR; Interventions: Genetic: DNA methylation analysis, Procedure: quality-of-life assessment, Radiation: Radiation | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: RADIATION; Name: Radiation; Assigned to Arm(s): Radiation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known whether radiation therapy and temozolomide are more effective than radiation therapy alone in treating glioblastoma multiforme.

PURPOSE: This randomized phase III trial is studying radiation therapy and temozolomide to see how well they work compared with radiation therapy alone in treating patients with newly diagnosed glioblastoma multiforme.


Options:
A: Arm Label: Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide, Genetic: DNA methylation analysis, Procedure: quality-of-life assessment | Arm Label: Radiation; Type: ACTIVE_COMPARATOR; Interventions: Genetic: DNA methylation analysis, Procedure: quality-of-life assessment, Radiation: Radiation | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: RADIATION; Name: Radiation; Assigned to Arm(s): Radiation
B: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
C: Arm Label: Arm 1 - Short Course Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy | Arm Label: Arm 2 - Standard Course Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 1 - Short Course Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 2 - Standard Course Radiotherapy
D: Intervention Type: DRUG; Name: Radiotherapy; Assigned to Arm(s): N/A

Answer: A